Perspective Therapeutics rises as experimental cancer drug shows promise

ReutersApr 20, 2026 10:18 AM

Shares of biotech firm Perspective Therapeutics CATX.A rise 3.3% to $4.34 premarket

Company says its experimental targeted radiation drug [212Pb]VMT-α-NET showed encouraging results in an early-stage trial in patients with advanced neuroendocrine tumors, a rare cancer that forms in hormone-making cells

Company says in one dose group, 43% of patients saw tumors shrink, with some showing further improvement since earlier data

The treatment was generally well-tolerated, with no serious kidney damage or severe blood disorders linked to the drug - CATX

Company plans to share more data later this year and prepare for talks with regulators in 2026

As of last close, shares up ~53% this year

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Asia-Pacific Stocks Rise Across the Board Monday as Easing Middle East Tensions Boost Market Sentiment

TradingKey - April 20: Major Asia-Pacific stock markets rose across the board on Monday, buoyed by widespread gains in global equity markets over the weekend and growing investor expectations for a de-escalation of tensions in the Middle East.

AST SpaceMobile Shares Plunge in Overnight Trading, What Happened? Will It Affect SpaceX?

TradingKey - In the early hours of April 19, AST SpaceMobile’s (ASTS.US) seventh broadband communication satellite, BlueBird 7, launched from Cape Canaveral aboard Blue Origin’s New Glenn rocket. While the rocket’s first stage was successfully recovered, the second stage deployed the satellite into

Is Netflix Still Worth Buying After a 10% Stock Slump? Who Is the Better Investment Compared to Disney?

TradingKey - After the market close on April 16, streaming giant Netflix delivered a seemingly impressive Q1 earnings report: revenue grew 16% year-over-year to $12.25 billion, exceeding the market expectation of $12.17 billion; earnings per share (EPS) reached $1.23, nearly doubling from $0.66 in t

Allbirds Ditches Sneakers and Pivots to AI Computing - Is BIRD Stock Still Worth Buying After a 600% Surge?

TradingKey - Allbirds surged 600% after announcing a full pivot to GPU leasing as NewBird AI. Shares pulled back 30% the next day. Key support $10, targets $13.30 and $15.90.

Nvidia Launches Ising Model Driving Quantum Sector Surge, QUBT vs IONQ, Which Is More Worth Investing In?

TradingKey - Following Nvidia’s launch of the Ising model, the quantum computing sector was rapidly galvanized; however, a company’s own commercialization progress remains the true determinant of its investment value. In comparison, IonQ’s revenue growth and execution capabilities are clearer, while QUBT is in an earlier stage, offering greater potential upside along with higher risk.

Featured Tools